Brokerages Set ConvaTec Group PLC (LON:CTEC) Price Target at GBX 306

ConvaTec Group PLC (LON:CTEC) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is GBX 306.

A number of equities research analysts recently commented on the company. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 300 target price on shares of ConvaTec Group in a research report on Wednesday, August 5th. Royal Bank Of Canada restated an “outperform” rating and set a GBX 315 price target on shares of ConvaTec Group in a report on Monday, August 3rd. JPMorgan Chase & Co. decreased their price objective on ConvaTec Group from GBX 307 to GBX 294 and set an “overweight” rating on the stock in a report on Friday, May 22nd. UBS Group reiterated a “buy” rating and set a GBX 375 target price on shares of ConvaTec Group in a research report on Monday, May 18th. Finally, Peel Hunt reissued an “add” rating and issued a GBX 270 target price on shares of ConvaTec Group in a report on Tuesday, August 4th.

Insider Buying and Selling

In other ConvaTec Group news, insider Tobias Hestler acquired 50,000 shares of the stock in a transaction on Thursday, August 6th. The stock was acquired at an average price of GBX 226 per share, for a total transaction of £113,000. 0.98% of the stock is owned by company insiders.

ConvaTec Group Stock Down 1.0%

CTEC opened at GBX 225.20 on Thursday. The firm has a 50-day simple moving average of GBX 223.76 and a two-hundred day simple moving average of GBX 221.25. ConvaTec Group has a 52 week low of GBX 193 and a 52 week high of GBX 259.30. The company has a market capitalization of £4.40 billion, a PE ratio of 26.19, a price-to-earnings-growth ratio of 0.93 and a beta of 0.77. The company has a quick ratio of 0.96, a current ratio of 1.93 and a debt-to-equity ratio of 121.83.

ConvaTec Group Company Profile

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.